script.reportAU
Rheumatology

Etanercept

Brand: Nepexto

PBAC's latest decision on Etanercept: Recommended with restriction (2025). Considered for Severe psoriatic arthritis, ankylosing spondylitis, severe active rheumatoid arthritis, severe chronic plaque psoriasis, and severe active juvenile idiopathic arthritis.

PBAC outcome
Recommended with restriction
Authority Required
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
20
first 2005
PBS spend
$89M
107,149 scripts · 2024

Eligible population

Adults and adolescents with severe psoriatic arthritis, ankylosing spondylitis, severe active rheumatoid arthritis, severe chronic plaque psoriasis, and children/adolescents with severe active juvenile idiopathic arthritis weighing 62.5 kg or more.

Therapy area
Rheumatology
Line of therapy
Any
Evidence base
Cost-minimisation
Primary endpoint
Cost-minimisation
Comparator
Enbrel (reference biologic), Brenzys (other etanercept biosimilar)
Economic model
Cost-minimisation
ICER note
Cost-minimisation analysis; no ICER calculated as this is a biosimilar with equi-effective dosing to existing PBS-listed etanercept brands.
ICER (historical)
$45k/QALY–$75k/QALY across 7 submissions (2005–2016) — the latest submission carried no numeric base case. No single PSD states this combined range; see source PSDs.

PBS expenditure

The Australian government paid $89M in PBS benefits for Etanercept in 2024 across 107,149 scripts, at $831 per script.

Submission history

Similar precedents

Open on full dashboard →